SYL116011

SYL116011 is a small interfering RNA (siRNA) therapeutic developed by Sylentis, a subsidiary of the PharmaMar Group, for the treatment of ocular allergies such as allergic conjunctivitis. The drug utilizes RNA interference (RNAi) technology to specifically target and silence the expression of ORAI1, a calcium channel protein that plays a critical role in the signaling pathways of allergic responses. By reducing ORAI1 levels, SYL116011 aims to decrease symptoms like swelling and tearing. Administered as a once-daily topical ophthalmic solution, it is designed to offer a more convenient dosing regimen and a better safety profile compared to traditional antihistamines, which often require multiple daily doses and can cause side effects like itchy eyes and drowsiness.